drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically engineered T cells modified to express a BCMA-targeted chimeric antigen receptor; upon BCMA engagement, induces MHC-independent T-cell activation (CD3ΞΆ with co-stimulation), expansion, cytokine release, and perforin/granzyme-mediated lysis of multiple myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a BCMA-targeted chimeric antigen receptor; upon BCMA binding, the CAR delivers CD3-zeta and co-stimulatory signals to drive MHC-independent T-cell activation, expansion, and cytokine release, resulting in perforin/granzyme-mediated lysis of BCMA-positive multiple myeloma cells.
drug_name
CBG002 CAR-T Cell Suspension
nct_id_drug_ref
NCT06705725